OBI-866 ”Immunogenic/Therapeutic Glycan Compositions And Uses Thereof“ Was Granted By USPTO
2022.Dec.19
Announcement on behalf of AP Biosciences to file application for Phase I human clinical trial of Bispecific Antibody, AP505, to US FDA
2022.Dec.09
Announcement on behalf of AP Biosciences that it obtains the Internal Control Special Audit Report by CPA
2022.Nov.28
Amendments to related matters that OBI forfeits part of subscription rights of Obigen’s cash capital increase and distributes the rights to its shareholders
2022.Nov.24
OBI sets target date of distribution of other benefits from forfeiture of subscription rights to its shareholders for Obigen’s 2022 cash capital increase
2022.Nov.24
The Company’s BOD resolved to forfeit part of subscription rights of Obigen’s cash capital increase and distribute the rights to its shareholders
2022.Nov.23
The Company correct the information on monetary loans extended to others filed on September and October 2022
2022.Nov.14
Announcement on behalf of AP Biosciences that application for Phase I human clinical trial of Bispecific Antibody, AP203, has been granted by TFDA
